I write in response to your Official Information Act request, dated 09 April 2019.
You requested the following information:
The number of clinical drug trials your DHB hosted in the 2017/2018 financial year + ongoing trials in 2019.
1. Could figures please be broken-down by:
•The number of sponsored clinical trials involving devices and pharmaceuticals.
•Phase 1 first-man-in clinical trials, and phase 2a/b safety and efficacy trials, phase 3 broader efficacy trials, and phase 4 post-marketing surveillance.
2.And whether these trials are:
•Investigator-initiated or industry-sponsored commercially contracted trials.
•Investigator-initiated studies of non-therapeutic interventions, e.g. new diagnostics or newapplications of existing diagnostics.
•Investigator-initiated observational studies including epidemiologic studies.
3.Can you please also provide the aggregate income figure your DHB obtained from trialsconducted in the 2017/2018 financial year.
•The information sought in this request is to be used as part of a report about DHB’s incomefrom hosting clinical trials.
Our response is attached